Can we delay the accelerated lung aging in COPD? anti-aging molecules and interventions

Current Drug Targets

Volumn 14, Issue 2, 2013, Pages 149-157

  Papaioannou, Andriana I ^a   Rossios, Christos ^b   Kostikas, Konstantinos ^c   Ito, Kazuhiro ^b  

^a SISMANOGLIO HOSPITAL   (Greece)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Aging; COPD; Inflammation; Oxidative stress; Sirtuins

Indexed keywords

ACETYLCYSTEINE; CARBOCISTEINE; CATECHIN; ERDOSTEINE; FUDOSTEINE; GENISTEIN; LAZAROID; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NORPHENAZONE; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; QUERCETIN; RAPAMYCIN; RESVERATROL; ROFLUMILAST; SILIBININ; SIRTUIN; SULFORAPHANE; TOCOPHEROL; TRANSCRIPTION FACTOR NRF2;

AGING; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIARRHEA; DNA DAMAGE; GENE EXPRESSION; HEADACHE; HUMAN; INFLAMMATION; LUNG FUNCTION; NAUSEA; NONHUMAN; OXIDATIVE STRESS; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PROTEIN CARBONYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENESCENCE; SMOKING CESSATION; TELOMERE SHORTENING;

AGE FACTORS; AGING; ANIMALS; DRUG DESIGN; HUMANS; INFLAMMATION; LUNG; MOLECULAR TARGETED THERAPY; OXIDATIVE STRESS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; SMOKING; SMOKING CESSATION;

EID: 84873116668     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450111314020003     Document Type: Article

References (111)

1. Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest 2009; 135: 173-80.
2. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977; 1: 1645-8.
3. Patel BD, Loo WJ, Tasker AD, et al. Smoking related COPD and facial wrinkling: is there a common susceptibility? Thorax 2006; 61: 568-71.
4. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-54.
5. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-89.
6. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332-8.
7. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. Available at: http://www.goldcopd.org. Last accessed on April 29, 2012.
8. Harman D. Free radical theory of aging: an update: increasing the functional life span. Ann N Y Acad Sci 2006; 1067: 10-21.
9. Galaris D, Mantzaris M, Amorgianiotis C. Oxidative stress and aging: the potential role of iron. Hormones (Athens) 2008; 7: 114-22.
10. Church DF, Pryor WA. Free-radical chemistry of cigarette smoke and its toxicological implications. Environ Health Perspect 1985; 64: 111-26.
11. Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med 1997; 156: 341-57.
12. Langen RC, Korn SH, Wouters EF. ROS in the local and systemic pathogenesis of COPD. Free Radic Biol Med 2003; 35: 226-35.
13. Kostikas K, Papatheodorou G, Psathakis K, et al. Oxidative stress in expired breath condensate of patients with COPD. Chest 2003; 124: 1373-80.
14. Schaberg T, Haller H, Rau M, et al. Superoxide anion release induced by platelet-activating factor is increased in human alveolar macrophages from smokers. Eur Respir J 1992; 5: 387-93.
15. Barreiro E, Schols AM, Polkey MI, et al. Cytokine profile in quadriceps muscles of patients with severe COPD. Thorax 2008; 63: 100-7.
16. Rahman I, Morrison D, Donaldson K, et al. Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med 1996; 154: 1055-60.
17. Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-52.
18. Nielson CP, Crowley JJ, Morgan ME, et al. Polymorphonuclear leukocyte inhibition by therapeutic concentrations of theophylline is mediated by cyclic-3',5'-adenosine monophosphate. Am Rev Respir Dis 1988; 137: 25-30.
19. Renkema TE, Postma DS, Noordhoek JA, et al. Influence of in vivo prednisolone on increased in vitro O2-generation by neutrophils in emphysema. Eur Respir J 1993; 6: 90-5.
20. Kaneko M, Suzuki K, Furui H, et al. Comparison of theophylline and enprofylline effects on human neutrophil superoxide production. Clin Exp Pharmacol Physiol 1990; 17: 849-59.
21. Lomas DA, Ip M, Chamba A, et al. The effect of in vitro and in vivo dexamethasone on human neutrophil function. Agents Actions 1991; 33: 279-85.
22. Moldeus P, Cotgreave IA, Berggren M. Lung protection by a thiolcontaining antioxidant: N-acetylcysteine. Respiration 1986; 50 Suppl 1: 31-42.
23. Rahman I, Macnee W. Antioxidant pharmacological therapies for COPD. Curr Opin Pharmacol 2012; 12: 256-65.
24. Bridgeman MM, Marsden M, Selby C, et al. Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue. Thorax 1994; 49: 670-5.
25. Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365: 1552-60.
26. Braga PC, Allegra L, Rampoldi C, et al. Long-lasting effects on rheology and clearance of bronchial mucus after short-term administration of high doses of carbocysteine-lysine to patients with chronic bronchitis. Respiration 1990; 57: 353-8.
27. Carpagnano GE, Resta O, Foschino-Barbaro MP, et al. Exhaled Interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMCLys). Eur J Pharmacol 2004; 505: 169-75.
28. Zheng CH, Ahmed K, Rikitomi N, et al. The effects of Scarboxymethylcysteine and N-acetylcysteine on the adherence of Moraxella catarrhalis to human pharyngeal epithelial cells. Microbiol Immunol 1999; 43: 107-13.
29. Zheng JP, Kang J, Huang SG, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet 2008; 371: 2013-8.
30. Dal Negro RW. Erdosteine: antitussive and anti-inflammatory effects. Lung 2008; 186 Suppl 1: S70-3.
31. Dal Negro R, Visconti M, Trevisan F, et al. Erdosteine enhances airway response to salbutamol in patients with mild-to-moderate COPD. Ther Adv Respir Dis 2008; 2: 271-7.
32. Cazzola M, Floriani I, Page CP. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta-analysis of individual patient data. Pulm Pharmacol Ther 2010; 23: 135-44.
33. Dal Negro RW, Visconti M, Tognella S, et al. Erdosteine affects eicosanoid production in COPD. Int J Clin Pharmacol Ther 2011; 49: 41-5.
34. Takahashi K, Mizuno H, Ohno H, et al. Effects of SS320A, a new cysteine derivative, on the change in the number of goblet cells induced by isoproterenol in rat tracheal epithelium. Jpn J Pharmacol 1998; 77: 71-7.
35. Osoata GO, Hanazawa T, Brindicci C, et al. Peroxynitrite elevation in exhaled breath condensate of COPD and its inhibition by fudosteine. Chest 2009; 135: 1513-20.
36. Takahashi K, Kai H, Mizuno H, et al. Effect of fudosteine, a new cysteine derivative, on mucociliary transport. J Pharm Pharmacol 2001; 53: 911-4.
37. Nagaoka S, Takishima T, Nagano H, et al. Phase III Clinical Study of SS320A. Double-blind Trial in Comparison with Placebo. Journal of Clinical Therapeutics & Medicines 2002; 18: 109-40.
38. Wang S, Lantz RC, Vermeulen MW, et al. Functional alterations of alveolar macrophages subjected to smoke exposure and antioxidant lazaroids. Toxicol Ind Health 1999; 15: 464-9.
39. Ito K, Ozasa H, Horikawa S. Edaravone protects against lung injury induced by intestinal ischemia/reperfusion in rat. Free Radic Biol Med 2005; 38: 369-74.
40. Franceschi C, Bonafe M, Valensin S, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000; 908: 244-54.
41. Rahman I, Kinnula VL, Gorbunova V, et al. SIRT1 as a therapeutic target in inflammaging of the pulmonary disease. Prev Med 2012; 54 Suppl: S20-8.
42. Meyer KC, Rosenthal NS, Soergel P, et al. Neutrophils and lowgrade inflammation in the seemingly normal aging human lung. Mech Ageing Dev 1998; 104: 169-81.
43. Barnes PJ. Transcription factors in airway diseases. Lab Invest 2006; 86: 867-72.
44. Kim HC, Mofarrahi M, Hussain SN. Skeletal muscle dysfunction in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008; 3: 637-58.
45. Barnes PJ. Future treatments for chronic obstructive pulmonary disease and its comorbidities. Proc Am Thorac Soc 2008; 5: 857-64.
46. Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 926-34.
47. Barnes PJ. Unexpected failure of anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 866-7.
48. Martorana PA, Beume R, Lucattelli M, et al. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 2005; 172: 848-53.
49. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009; 374: 695-703.
50. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685-94.
51. Birrell MA, Wong S, Hardaker EL, et al. IkappaB kinase-2-independent and-dependent inflammation in airway disease models: relevance of IKK-2 inhibition to the clinic. Mol Pharmacol 2006; 69: 1791-800.
52. Lomas DA, Lipson DA, Miller BE, et al. An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. J Clin Pharmacol 2012; 52: 416-24.
53. Karrasch S, Holz O, Jorres RA. Aging and induced senescence as factors in the pathogenesis of lung emphysema. Respir Med 2008; 102: 1215-30.
54. Graakjaer J, Bischoff C, Korsholm L, et al. The pattern of chromosome-specific variations in telomere length in humans is determined by inherited, telomere-near factors and is maintained throughout life. Mech Ageing Dev 2003; 124: 629-40.
55. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985; 43: 405-13.
56. Herrera E, Samper E, Blasco MA. Telomere shortening in mTR-/-embryos is associated with failure to close the neural tube. EMBO J 1999; 18: 1172-81.
57. Ling S, Zhou L, Li H, et al. Effects of 17beta-estradiol on growth and apoptosis in human vascular endothelial cells: influence of mechanical strain and tumor necrosis factor-alpha. Steroids 2006; 71: 799-808.
58. Grasselli A, Nanni S, Colussi C, et al. Estrogen receptor-alpha and endothelial nitric oxide synthase nuclear complex regulates transcription of human telomerase. Circ Res 2008; 103: 34-42.
59. Nicholls C, Li H, Wang JQ, et al. Molecular regulation of telomerase activity in aging. Protein Cell 2011; 2: 726-38.
60. Gonzalez-Suarez E, Geserick C, Flores JM, et al. Antagonistic effects of telomerase on cancer and aging in K5-mTert transgenic mice. Oncogene 2005; 24: 2256-70.
61. Tomas-Loba A, Flores I, Fernandez-Marcos PJ, et al. Telomerase reverse transcriptase delays aging in cancer-resistant mice. Cell 2008; 135: 609-22.
62. Jaskelioff M, Muller FL, Paik JH, et al. Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature 2011; 469: 102-6.
63. Savale L, Chaouat A, Bastuji-Garin S, et al. Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 179: 566-71.
64. Tsuji T, Aoshiba K, Nagai A. Alveolar cell senescence in patients with pulmonary emphysema. Am J Respir Crit Care Med 2006; 174: 886-93.
65. Alder JK, Guo N, Kembou F, et al. Telomere length is a determinant of emphysema susceptibility. Am J Respir Crit Care Med 2011; 184: 904-12.
66. Atzmon G, Cho M, Cawthon RM, et al. Evolution in health and medicine Sackler colloquium: Genetic variation in human telomerase is associated with telomere length in Ashkenazi centenarians. Proc Natl Acad Sci U S A 2010; 107 Suppl 1: 1710-7.
67. Sprouse AA, Steding CE, Herbert BS. Pharmaceutical regulation of telomerase and its clinical potential. J Cell Mol Med 2012; 16: 1-7.
68. Fauce SR, Jamieson BD, Chin AC, et al. Telomerase-based pharmacologic enhancement of antiviral function of human CD8+ T lymphocytes. J Immunol 2008; 181: 7400-6.
69. Pearce VP, Sherrell J, Lou Z, et al. Immortalization of epithelial progenitor cells mediated by resveratrol. Oncogene 2008; 27: 2365-74.
70. Xia L, Wang XX, Hu XS, et al. Resveratrol reduces endothelial progenitor cells senescence through augmentation of telomerase activity by Akt-dependent mechanisms. Br J Pharmacol 2008; 155: 387-94.
71. Lee GD, Wilson MA, Zhu M, et al. Dietary deprivation extends lifespan in Caenorhabditis elegans. Aging Cell 2006; 5: 515-24.
72. Mostoslavsky R, Chua KF, Lombard DB, et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 2006; 124: 315-29.
73. Chung S, Yao H, Caito S, et al. Regulation of SIRT1 in cellular functions: role of polyphenols. Arch Biochem Biophys 2010; 501: 79-90.
74. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009; 460: 587-91.
75. Faner R, Rojas M, Macnee W, et al. Abnormal Lung Aging in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2012.
76. Brunet A, Sweeney LB, Sturgill JF, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004; 303: 2011-5.
77. Ota H, Akishita M, Eto M, et al. Sirt1 modulates premature senescence-like phenotype in human endothelial cells. J Mol Cell Cardiol 2007; 43: 571-9.
78. Rajendrasozhan S, Yang SR, Kinnula VL, et al. SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 861-70.
79. Yang SR, Wright J, Bauter M, et al. Sirtuin regulates cigarette smoke-induced proinflammatory mediator release via RelA/p65 NF-kappaB in macrophages in vitro and in rat lungs in vivo: implications for chronic inflammation and aging. Am J Physiol Lung Cell Mol Physiol 2007; 292: L567-76.
80. Nakamaru Y, Vuppusetty C, Wada H, et al. A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J 2009; 23: 2810-9.
81. Wood JG, Rogina B, Lavu S, et al. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 2004; 430: 686-9.
82. Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007; 450: 712-6.
83. Kawahara TL, Michishita E, Adler AS, et al. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell 2009; 136: 62-74.
84. Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 2005; 65: 3980-5.
85. Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51.
86. Sato A, Hirai T, Imura A, et al. Morphological mechanism of the development of pulmonary emphysema in klotho mice. Proc Natl Acad Sci U S A 2007; 104: 2361-5.
87. Suga T, Kurabayashi M, Sando Y, et al. Disruption of the klotho gene causes pulmonary emphysema in mice. Defect in maintenance of pulmonary integrity during postnatal life. Am J Respir Cell Mol Biol 2000; 22: 26-33.
88. Kurosu H, Yamamoto M, Clark JD, et al. Suppression of aging in mice by the hormone Klotho. Science 2005; 309: 1829-33.
89. Yamamoto M, Clark JD, Pastor JV, et al. Regulation of oxidative stress by the anti-aging hormone klotho. J Biol Chem 2005; 280: 38029-34.
90. Partridge L, Gems D. Mechanisms of ageing: public or private? Nat Rev Genet 2002; 3: 165-75.
91. Nagai T, Yamada K, Kim HC, et al. Cognition impairment in the genetic model of aging klotho gene mutant mice: a role of oxidative stress. FASEB J 2003; 17: 50-2.
92. Zhu H, Itoh K, Yamamoto M, et al. Role of Nrf2 signaling in regulation of antioxidants and phase 2 enzymes in cardiac fibroblasts: protection against reactive oxygen and nitrogen species-induced cell injury. FEBS Lett 2005; 579: 3029-36.
93. McMahon M, Itoh K, Yamamoto M, et al. Keap1-dependent Proteasomal Degradation of Transcription Factor Nrf2 Contributes to the Negative Regulation of Antioxidant Response Elementdriven Gene Expression. Journal of Biological Chemistry 2003; 278: 21592-600.
94. Rangasamy T, Cho CY, Thimmulappa RK, et al. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J Clin Invest 2004; 114: 1248-59.
95. Ishii Y, Itoh K, Morishima Y, et al. Transcription factor Nrf2 plays a pivotal role in protection against elastase-induced pulmonary inflammation and emphysema. J Immunol 2005; 175: 6968-75.
96. Malhotra D, Thimmulappa RK, Mercado N, et al. Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients. J Clin Invest 2011; 121: 4289-302.
97. Dazert E, Hall MN. mTOR signaling in disease. Curr Opin Cell Biol 2011; 23: 744-55.
98. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149: 274-93.
99. Kapahi P, Zid BM, Harper T, et al. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol 2004; 14: 885-90.
100. Vellai T, Takacs-Vellai K, Zhang Y, et al. Genetics: influence of TOR kinase on lifespan in C. elegans. Nature 2003; 426: 620.
101. Kaeberlein M, Powers RW, 3rd, Steffen KK, et al. Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. Science 2005; 310: 1193-6.
102. Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009; 460: 392-5.
103. Lin SJ, Defossez PA, Guarente L. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science 2000; 289: 2126-8.
104. Kaeberlein M, Kirkland KT, Fields S, et al. Sir2-independent life span extension by calorie restriction in yeast. PLoS Biol 2004; 2: E296.
105. Wilkinson JE, Burmeister L, Brooks SV, et al. Rapamycin slows aging in mice. Aging Cell 2012; 11: 675-82.
106. Schiele TM, Leibig M, Rieber J, et al. Five-year clinical follow-up after sirolimus-eluting stent implantation for the treatment of coronary in-stent restenosis. Coronary artery disease 2011; 22: 188-93.
107. McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. The New England journal of medicine 2011; 364: 1595-606.
108. Anisimov VN. Metformin for aging and cancer prevention. Aging (Albany NY) 2010; 2: 760-74.
109. Anisimov VN, Berstein LM, Popovich IG, et al. If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice. Aging (Albany NY) 2011; 3: 148-57.
110. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. The Journal of clinical investigation 2001; 108: 1167-74.
111. Rabe KF, Bateman ED, O'Donnell D, et al. Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005; 366: 563-71.